Aug 15 (Reuters) - Achillion Pharmaceuticals Inc said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no detectable levels of the virus four weeks after completing the therapy.
The mid-stage trial tested Achillion’s drug, ACH-3102, in 12 patients in combination with Gilead Sciences Inc’s Sovaldi, also known as sofosbuvir.
Achillion said it would begin treating 12 additional patients for six weeks with a once-daily dose of ACH-3102 and sofosbuvir.
The trial excluded the older hepatitis C drug ribavirin, which can cause rashes, anemia and other side effects.
Achillion shares rose about 10 percent to $9.25 in premarket trading. (Reporting by Anand Basu in Bangalore; Editing by Simon Jennings)